XML 27 R14.htm IDEA: XBRL DOCUMENT
v3.25.2

Investments | 6 Months Ended
--- | ---
Jun. 30, 2025
Investments [Abstract] |
Investments | 7. INVESTMENT S ​ Equity Method Investments ​ The changes in our equity method investments were as follows: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended | ​ | Six Months Ended | ​
​ | ​ | June 30, | ​ | June 30, | ​
​ |  | 2025 |  | 2024 |  | 2025 |  | 2024 |
​ | ​ | (in thousands) | ​
Beginning balance | ​ | $ | 33,555 | ​ | $ | 45,693 | ​ | $ | 35,532 | ​ | $ | 46,503 | ​
Contributions | ​ | ​ | 513 | ​ | ​ | 665 | ​ | ​ | 1,391 | ​ | ​ | 1,290 | ​
Net loss on equity method investments | ​ | ​ | (1,536) | ​ | ​ | (152) | ​ | ​ | (3,542) | ​ | ​ | (705) | ​
Distributions received | ​ | ​ | (2,904) | ​ | ​ | (1,118) | ​ | ​ | (3,753) | ​ | ​ | (2,000) | ​
Ending balance | ​ | $ | 29,628 | ​ | $ | 45,088 | ​ | $ | 29,628 | ​ | $ | 45,088 | ​
​ Net loss on equity method investments represents our share of the income or loss of the equity method investments. ​ Infinitum ​ During 2022, we purchased shares of Series D Preferred Stock (“Series D Preferred Stock”) in Infinitum for $42.0 million. Infinitum is a Texas-based startup developer and manufacturer of electric motors featuring printed circuit board stators. On September 8, 2023, we purchased $24.6 million of Series E Preferred Stock (“Series E Preferred Stock” and, together with the “Series D Preferred Stock,” the “Infinitum Preferred Stock”) in Infinitum. The Infinitum Preferred Stock provides for non-cumulative dividends when and if declared by Infinitum’s board of directors. Each share of Infinitum Preferred Stock is convertible, at any time, at our option, into shares of common stock of Infinitum. We account for our ownership interest in Infinitum as an equity investment without a readily determinable fair value. Absent an observable price change, it is not practicable to estimate the fair value of our investment in Infinitum because of the lack of a quoted market price for our ownership interests. Therefore, we use a measurement alternative other than fair value to account for our investment. ​ Ascend ​ On August 22, 2023, we purchased shares of Series D Preferred Stock (the “Ascend Series D Preferred Stock”) in Ascend for $25.0 million which was accounted for as an equity investment without a readily determinable fair value because of the lack of quoted market prices. Ascend is a U.S.-based manufacturer and recycler of sustainable, engineered battery materials for electric vehicles. In June 2025, Ascend raised new capital through a convertible note financing. Under the terms of the convertible note and the resulting recapitalization, all existing shares of each outstanding series of preferred stock were converted into common stock on a 1:1 basis for stockholders that participated in the convertible note purchase, or on a 3:1 basis if they did not participate. ​ We elected to participate in the recapitalization of Ascend with a $3.1 million commitment to purchase convertible debt. We have funded $2.1 million of our commitment as of June 30, 2025. The convertible notes provide for a redemption in two years for an amount equal to the greater of (a) a multiple of each stockholder’s investment in the convertible notes as determined by the level of participation or (b) the principal amount of each stockholder’s investment in the convertible notes plus an annual interest rate of 15%. Based on our level of participation, our convertible notes provide for a multiple of 12 times our funded commitment at redemption. We concluded that these convertible notes represent available-for-sale debt securities. We do not intend to sell our debt securities (which are subject to certain transfer restrictions) and believe it is likely that we will not be required to sell them before redemption. As a result of our participation in the recapitalization, our shares of Ascend Series D Preferred Stock converted into common stock on a 1:1 basis. ​ The following table reflects our debt securities holdings: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | June 30, 2025 | ​
​ | ​ | Cost Basis | ​ | Unrealized Gains (1) | ​ | Fair Value | ​
​ | ​ | (in thousands, except unit data) | ​
Debt Securities | ​ | $ | 2,127 | ​ | $ | 10,919 | ​ | $ | 13,046 | ​
(1) | Unrealized gains in our debt securities are included in the Change in unrealized gains (losses) on debt securities line item within our condensed consolidated statements of comprehensive income.
​ As discussed in Note 4 – Fair Value Measurements, we determined the fair value of the debt securities was $13.0 million. In the same models used to determine the value of the debt securities, we determined that the common stock we hold in Ascend as a result of the conversion had no value, resulting in an impairment charge of $25.0 million included in our condensed consolidated statements of income. The $25.0 million impairment charge is a Level 3 fair value measurement and is included within our Other, Corporate and Elimination category.

X
- Definition The entire disclosure for equity method investments and marketable securities without readily determinable fair value. + References No definition available. + Details
Name: | arlp_InvestmentsInEquityMethodAndMarketableEquitySecuritiesWithoutReadilyDeterminableFvDisclosureTextBlock
Namespace Prefix: | arlp_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_InvestmentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration